| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:2679-2684.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
From the Departments of Medicine (K.M., K.N., K.A., M.C., H.N., S.T.), Regenerative Medicine and Tissue Engineering (N.N.), Anesthesiology (M.K.), Transfusion Medicine (S.M.), Radiology (M.H., R.T.), and Organ Transplantation (T.N.), National Cardiovascular Center, Osaka; and the Department of Clinical Laboratory (T.S.), Osaka Minami Medical Center, Osaka, Japan.
Correspondence to Dr Satoshi Takeshita, MD, FACC, Department of Medicine (Cardiology), National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail stake{at}muse.ocn.ne.jp
Received June 9, 2006; revision received September 19, 2006; accepted September 21, 2006.
Background The short-term clinical benefits of bone marrow mononuclear cell transplantation have been shown in patients with critical limb ischemia. The purpose of this study was to assess the long-term safety and efficacy of bone marrow mononuclear cell transplantation in patients with thromboangiitis obliterans.
Methods and Results Eleven limbs (3 with rest pain and 8 with an ischemic ulcer) of 8 patients were treated by bone marrow mononuclear cell transplantation. The patients were followed up for clinical events for a mean of 684±549 days (range 103 to 1466 days). At 4 weeks, improvement in pain was observed in all 11 limbs, with complete relief in 4 (36%). Pain scale (visual analog scale) score decreased from 5.1±0.7 to 1.5±1.3. An improvement in skin ulcers was observed in all 8 limbs with an ischemic ulcer, with complete healing in 7 (88%). During the follow-up, however, clinical events occurred in 4 of the 8 patients. The first patient suffered sudden death at 20 months after transplantation at 30 years of age. The second patient with an incomplete healing of a skin ulcer showed worsening of the lesion at 4 months. The third patient showed worsening of rest pain at 8 months. The last patient developed an arteriovenous shunt in the foot at 7 months, which spontaneously regressed by 1 year.
Conclusions In the present unblinded and uncontrolled pilot study, long-term adverse events, including death and unfavorable angiogenesis, were observed in half of the patients receiving bone marrow mononuclear cell transplantation. Given the current incomplete knowledge of the safety and efficacy of this strategy, careful long-term monitoring is required for future patients receiving this treatment.
This article has been cited by other articles:
![]() |
J. R. Lindner, L. Womack, E. J. Barrett, J. Weltman, W. Price, N. L. Harthun, S. Kaul, and J. T. Patrie Limb Stress-Rest Perfusion Imaging With Contrast Ultrasound for the Assessment of Peripheral Arterial Disease Severity J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 343 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Kramer Skeletal Muscle Perfusion in Peripheral Arterial Disease: A Novel End Point for Cardiovascular Imaging J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 351 - 353. [Full Text] [PDF] |
||||
![]() |
Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114: 2679-2684 Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2008; 20(1): 100 - 102. [Abstract] [PDF] |
||||
![]() |
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases JAMA, February 27, 2008; 299(8): 925 - 936. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kanayasu-Toyoda, A. Ishii-Watabe, T. Suzuki, T. Oshizawa, and T. Yamaguchi A New Role of Thrombopoietin Enhancing ex Vivo Expansion of Endothelial Precursor Cells Derived from AC133-positive Cells J. Biol. Chem., November 16, 2007; 282(46): 33507 - 33514. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hirsch Critical Limb Ischemia and Stem Cell Research: Anchoring Hope With Informed Adverse Event Reporting Circulation, December 12, 2006; 114(24): 2581 - 2583. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |